Q&A: Lundbeck’s head of R&D on letting ‘biology speak’ in neuroscience
Johan Luthman has been running R&D at Lundbeck since 2019, and part of the neuroscience leader’s remit is helping steer development of a promising but still-experimental seizure medication that the...
View ArticleRallybio ends development in rare disorder; ImmunityBio raises $75M
Plus, news about KalVista, Kaken Pharmaceutical, Lyell and Tango Therapeutics: Rallybio stops work on RLYB212 in rare immune disorder: The company had been testing the drug to see if it could prevent...
View ArticleNovo Nordisk, HHS clash in court over IRA drug selection
Novo Nordisk focused on a unique argument in federal appeals court on Tuesday in a case that will consider the extent to which the judiciary can review which drugs HHS says are eligible for Medicare ...
View ArticleKennedy's FDA cuts raise questions about 'trigger' for user fees
Last week's thousands of FDA job cuts will take a major chunk out of what the agency spends each year as part of its nearly $7 billion budget. But they could — theoretically — also have other ...
View ArticleWhat stock market chaos means for health tech
The markets have been volatile over the past few days, turned upside down by the tariffs announced by President Donald Trump. No industry has been spared. Our corner of health ...
View ArticleNIH appeals nationwide block on indirect cost cuts
The Trump administration on Tuesday said it will challenge a federal judge’s order that blocks its planned 15% rate limit on indirect cost reimbursements for NIH grant recipients nationwide. The...
View ArticleHouse panel mulls ways to boost struggling biosimilar market
The state of the US biosimilar market isn't as healthy as it should be despite significant advances in the past decade, health policy experts told a House panel on Tuesday. The US still struggles to ...
View ArticlePharma CEOs warn EU of potential US exodus as trade war continues
Executives of major pharmaceutical companies warned the European Union that they’re likely to take the US’ side amid the threat of new tariffs. The European Federation of Pharmaceutical Industries and...
View ArticlePharma is next in line as Trump says tariffs are coming 'very shortly'
President Donald Trump warned on Tuesday evening that “major” pharmaceutical tariffs will be coming “very shortly,” after previously exempting drugs from his earlier levy announcements. “We’re gonna do...
View ArticleNovo Nordisk looks to Brazil to boost GLP-1 manufacturing with $1B+ budget
Novo Nordisk is pouring 6.4 billion Brazilian reais ($1.05 billion) into a factory in Brazil, to ramp up production of its blockbuster GLP-1 drugs after it forecast relatively sluggish growth earlier...
View ArticleIdorsia’s blood pressure pill no longer requires a REMS; Solu raises $41M
Plus, news about Vincerx and Cytora: Idorsia’s Tryvio gets safety restriction removed: Patients taking Idorsia’s blood pressure pill no longer have to take part in a drug safety program. The FDA ...
View ArticleBiotech market meltdown will leave some startups looking at survival playbook
It’s a biotech environment without many good choices. Even before President Donald Trump’s tariff announcement pushed stock indices toward a bear market, biotech M&A has been virtually nonexistent,...
View ArticleICER outlines ways to increase GLP-1 access as costs rise
The Institute for Clinical and Economic Review, the nonprofit drug pricing watchdog, released a new report on Wednesday outlining potential federal policy solutions to increase access to blockbuster...
View ArticleFirings of HHS' probationary workers can proceed, appeals court says
HHS and 19 other government agencies can follow through with firing thousands of probationary workers after a federal appeals court paused a lower court's order. Wednesday's ruling by the US Court of ...
View ArticleExclusive: Cardiometabolic biotech gets $57.5M Series B, with help from...
A biotech incubated by RA Capital has secured a $57.5 million Series B to begin a mid-stage trial for its cardio drug this quarter and get to a readout in late 2026. Imbria Pharmaceuticals has ...
View ArticleStudy: Therapy AI chatbot shows promising results
A trial of an AI chatbot built for mental health treatment has shown that it can reduce symptoms of conditions like anxiety and depression. The study published in NEJM AI ran ...
View ArticleBiotech CEOs to Cassidy: We're already seeing the effects of FDA's staff cuts
Biopharma companies with pending applications at the FDA have "already encountered regulatory difficulties that we believe are the consequences of the FDA’s loss of experienced staff," more than 100...
View ArticleAlzheon’s amyloid-targeting pill fails another Alzheimer’s Phase 3
Alzheon’s controversial, decade-long bet that a failed Alzheimer’s drug could offer bigger benefits to a subset of patients at the highest risk for the disease has ended in another disappointment. On...
View Article#AAN25: J&J, argenx keep rolling out myasthenia gravis data, plus more
Last weekend, researchers gathered in San Diego for the American Academy of Neurology’s annual meeting to discuss the latest advancements and clinical trial data across the neuroscience field. Among...
View Article